Treatment with the FXR agonist CDCA or GW4064 leads to apoptosis in breast cancer cell lines with distinct phenotypes, MCF-10A (normal), MCF-7 (receptor positive), and MDA-MB-231 and MDA-MB-468 (triple negative), and decreases the proliferation of tamoxifen-resistant MCF-7TR1 cells [127,128]. Here, NR1H4 is linked to breast cancer.